12.04.2022 | Tracker

Product Launch Tracker: HCPs discuss approvals for several cancer treatments and a fourth dose of COVID-19 vaccines

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout March 2022 we tracked the global conversations of 2,225 HCPs who posted 3,212 English-language Twitter posts about the launches and approvals of new products.

A graph showing HCP mentions of product launches on Twitter

In March, the list of approved chimeric antigen receptor (CAR) T-cell therapies grew by 1 as Johnson & Johnson and Legend Biotech’s ciltacabtagene autoleucel (cits-cel) received approval for treatment of relapsed and refractory multiple myeloma. HCPs shared in the excitement of the sustained clinical responses and long-lasting effect which would bring about hope for a future in patient lives

Another product to gain approval was Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was the first targeted radiogland therapy approved by the FDA for the treatment of an advanced type of prostate cancer. There were generally positive reactions from HCPs stating it is a much needed option for patients even though it had a slightly odd name

HCPs also shared the news of the FDA’s approval of Vonjo (pacritinib) for the treatment of adults with a subtype of myelofibrosis. HCPs celebrated this approval, heralding it as an important step forward and voiced hope for more global approvals to follow.

HCPs also commented on Bristol Myers Squibb’s product Opdivo (nivolumab), which was recently approved by the FDA for use with neoadjuvant chemotherapy in certain adult patients with resectable non-small cell lung cancer (NSCLC). HCPs spoke positively about this approval describing it as a major advance for patients with NSCLC.

Another nivolumab based treatment for BMS also received approval in March, with the FDA recommending Opdualag (relatlimab and nivolumab) for patients who are 12 years of age or older and who have unresectable or metastatic melanoma. HCPs again responded well to this approval, voicing their happiness for having another frontline treatment option for melanoma.

Finally, a talking point for HCPs at the end of the month was the FDA’s decision to approve a fourth COVID-19 shot for both Pfizer-BioNTech and the Moderna vaccines in those aged 50 and older. HCPs continued to be positive about the vaccines and encouraged the public to join them in getting a second booster jab.

The three most shared links from HCPs discussing product launches in February were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 March and 31 March 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 March and 31 March 2022, there were 3,212 HCP mentions of new pharmaceutical product launches and drug approvals from 2,225 unique HCP authors from around the world.

View the latest and archived trackers here

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next

19.10.2022 | Article

HCPs express hope, urgency and drive to tackle AMR

AMR has sometimes been labelled the ‘silent pandemic’......

By Jamie Doggett

02.12.2020 | Article

Vaccine efficacies dominate news, and HCPs support calls for robust public health roll out strategies

Discover what healthcare professionals (HCPs) think about COVID-19 vaccines

By Aaron Pitkin

View all articles >